These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 342311)
1. Clinical trials with a new influenza subunit vaccine in adults and children. Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of the immune response to influenza virus subunit vaccines. Webster RG; Glezen WP; Kasel JA; Laver WG Dev Biol Stand; 1977 Jun 1-3; 39():243-8. PubMed ID: 604104 [TBL] [Abstract][Full Text] [Related]
3. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines. Kuwert EK; Höher PG; Werner J; Scheiermann N; Thraenhart O; Müller B; Kleber G Dev Biol Stand; 1977 Jun 1-3; 39():77-83. PubMed ID: 604137 [TBL] [Abstract][Full Text] [Related]
4. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. Lina B; Fletcher MA; Valette M; Saliou P; Aymard M Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616 [TBL] [Abstract][Full Text] [Related]
6. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981 [TBL] [Abstract][Full Text] [Related]
7. Influenza immunization in children and young adults: clinical reactions and total and IgM antibody responses after immunization with whole-virus or split-product influenza vaccines. Bernstein DI; Zahradnik JM; DeAngelis CJ; Cherry JD Am J Dis Child; 1982 Jun; 136(6):513-7. PubMed ID: 7046421 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765 [TBL] [Abstract][Full Text] [Related]
9. [Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]. Kuwert E; Werner J; Franke G; Paulus W Zentralbl Bakteriol Orig A; 1979 Jun; 244(1):1-16. PubMed ID: 92113 [TBL] [Abstract][Full Text] [Related]
10. Human responses to purified surface antigen invluenza vaccine (Fluvirin). Stones PB; Furminger IG; Kerr J Dev Biol Stand; 1977 Jun 1-3; 39():239-42. PubMed ID: 604103 [TBL] [Abstract][Full Text] [Related]
11. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Bernstein DI; Zahradnik JM; DeAngelis CJ; Cherry JD Pediatrics; 1982 Apr; 69(4):404-8. PubMed ID: 7070886 [TBL] [Abstract][Full Text] [Related]
12. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361 [TBL] [Abstract][Full Text] [Related]
13. [Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults]. Profeta ML; Bigatello A; Vacchini V; Bramati L; Ferrante P Boll Ist Sieroter Milan; 1980 Jan; 58(6):457-74. PubMed ID: 6778485 [TBL] [Abstract][Full Text] [Related]
14. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
15. [Field trial with a new type of influenza subunit vaccine (author's transl)]. Kunz C; Hofmann H Wien Klin Wochenschr; 1976 Aug; 88(15):504-8. PubMed ID: 997532 [TBL] [Abstract][Full Text] [Related]
16. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951 [TBL] [Abstract][Full Text] [Related]
17. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G; Greenbaum E; Zakay-Rones Z Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048 [TBL] [Abstract][Full Text] [Related]
18. Reactogenicity to primary and repeated vaccination with influenza split virus vaccine. Hennessen W; Mauler R; Gruschkau H; Lehmann HG Dev Biol Stand; 1977 Jun 1-3; 39():289-93. PubMed ID: 604110 [TBL] [Abstract][Full Text] [Related]
19. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010 [TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers. Hrabar A; Vodopija I; André FE; Mitchell JR; Maassab HF; Hennessy AV; Davenport FM Dev Biol Stand; 1977 Jun 1-3; 39():53-60. PubMed ID: 342317 [No Abstract] [Full Text] [Related] [Next] [New Search]